{
    "info": {
        "nct_id": "NCT04810091",
        "official_title": "TELEHEART: Telotristat Ethyl in a Heart Biomarker Study",
        "inclusion_criteria": "* Patients who are >= 18 years old will be eligible for the study\n* Histopathologically-confirmed,metastatic neuroendocrine tumor and/or locally/regionally advanced neuroendocrine tumor\n* Documented history of carcinoid syndrome based on clinical parameters\n* Currently receiving stable-dose somatostatin analog (SSA) therapy defined as >= 2 months\n\n  * Dose of long-acting release (LAR) or depot SSA therapy and on at least:\n\n    * Octreotide LAR at 30 mg every 4 weeks\n    * Lanreotide depot at 120 mg every 4 weeks\n    * Patients who cannot tolerate SSA therapy at a level indicated above will be allowed to enter at their highest tolerated dose\n* Ability and willingness to provide written informed consent\n* Patients of childbearing potential must agree to use an adequate method of contraception during the study and for 30 days after the last dose of telotristat ethyl\n\n  * Childbearing potential is defined as those who have not undergone surgical sterilization (eg. documented hysterectomy, tubal ligation, or bilateral salpingo-oophorectomy) or those who are not considered postmenopausal (defined as 12 months of spontaneous amenorrhea).\n  * Adequate methods of contraception, defined as having a failure rate of < 1% per year, for patients or their partner include the following: condom with spermicidal gel, diaphragm with spermicidal gel, intrauterine device, surgical sterilization, vasectomy, oral contraceptive pill, depo-progesterone injections, progesterone implant (ie, Implanon), patch (Ortho Evra), NuvaRing, and abstinence. If a patient is not sexually active but becomes active, he or his partner should use medically accepted forms of contraception\n* Eastern Cooperative Oncology Group (ECOG) 0-2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Previous exposure to telotristat ethyl (XERMELO) in the last 3 months\n* History of active treatment for malignancy, other than neuroendocrine tumor (malignancies that in the opinion of the Investigator are considered cured, may participate)\n* Treatment with any tumor directed therapy, including interferon, chemotherapy, mechanistic target of rapamycin (mTOR) inhibitors < 4 weeks prior to screening, or hepatic embolization, radiotherapy, peptide receptor radionuclide therapy, and/or tumor debulking < 12 weeks prior to screening\n* History of short bowel syndrome or other known causes of diarrhea unrelated to carcinoid syndrome\n* Clinically significant (as per primary investigators judgement) cardiac arrhythmia, bradycardia, tachycardia that would compromise patient safety or the outcome of the study\n* Estimated glomerular filtration rate estimated glomerular filtration rate (eGFR) < 30 ml/min\n* Hepatic laboratory values of aspartate transaminase (AST) or alanine aminotransferase (ALT):\n\n  * > 5 x upper limit of normal (ULN) if patient has documented history of hepatic metastases; or\n  * > 2.5 x ULN if no liver metastases are present\n* Pregnant or lactating patients\n* Patients receiving everolimus due to poor response to SSA\n* Life expectancy < 6 months\n* Any other clinically significant laboratory abnormality that would compromise patient safety or the outcome of the study as per primary investigators judgement\n* Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study including as per primary investigators judgement, but not limited to:\n\n  * Arrhythmia causing hemodynamic compromise\n  * Symptomatic severe valvular disease\n  * Symptomatic congestive heart failure classified by New York Heart Association (NYHA) class IV\n  * Evidence of ischemia on electrocardiography (ECG) with chest pain\n  * Unstable angina pectoris\n* Current complaints of persistent constipation or history of chronic constipation, bowel obstruction or fecaloma within the past 6 months\n* Investigator assessment of known history and/or uncontrolled hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV)-1 or HIV-2\n* History of substance or alcohol abuse (Diagnostic and Statistical Manual of Mental Disorders 5th edition [DSM-V] Criteria for Substance-Related Disorders) within the past 2 years\n* History of galactose intolerance, deficiency of Lapp lactase, or glucose-galactose malabsorption\n* Receipt of any investigational agent or study treatment (other treatment nor approved by Food and Drug Administration [FDA] for carcinoid syndrome or carcinoid heart disease) within the past 30 days\n* Existence of any surgical or medical condition that, in the judgment of the Investigator, might compromise patient safety or the outcome of the study\n* Presence of any clinically significant findings (relative to the patient population) during review of medical history or upon PE that, in the investigator's opinion, would compromise patient safety or the outcome of the study (e.g., psychiatric illness/social situations that would limit compliance with study requirements)\n* Unable or unwilling to communicate or cooperate with the Investigator for any reason",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are >= 18 years old will be eligible for the study",
            "criterions": [
                {
                    "exact_snippets": "Patients who are >= 18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Dose of long-acting release (LAR) or depot SSA therapy and on at least:",
            "criterions": [
                {
                    "exact_snippets": "Dose of long-acting release (LAR) or depot SSA therapy",
                    "criterion": "long-acting release (LAR) or depot SSA therapy dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": "specified (not detailed in snippet)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients of childbearing potential must agree to use an adequate method of contraception during the study and for 30 days after the last dose of telotristat ethyl",
            "criterions": [
                {
                    "exact_snippets": "Patients of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use an adequate method of contraception during the study and for 30 days after the last dose of telotristat ethyl",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the study",
                                "for 30 days after the last dose of telotristat ethyl"
                            ]
                        },
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "adequate method"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability and willingness to provide written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Ability ... to provide written informed consent",
                    "criterion": "ability to provide written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to provide written informed consent",
                    "criterion": "willingness to provide written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Octreotide LAR at 30 mg every 4 weeks",
            "criterions": [
                {
                    "exact_snippets": "Octreotide LAR at 30 mg every 4 weeks",
                    "criterion": "Octreotide LAR administration",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": "=",
                                "value": 30,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "every 4 weeks"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lanreotide depot at 120 mg every 4 weeks",
            "criterions": [
                {
                    "exact_snippets": "Lanreotide depot at 120 mg every 4 weeks",
                    "criterion": "Lanreotide depot administration",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": "=",
                                "value": 120,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "every 4 weeks"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histopathologically-confirmed,metastatic neuroendocrine tumor and/or locally/regionally advanced neuroendocrine tumor",
            "criterions": [
                {
                    "exact_snippets": "Histopathologically-confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "histopathology"
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic neuroendocrine tumor",
                    "criterion": "neuroendocrine tumor",
                    "requirements": [
                        {
                            "requirement_type": "metastatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "locally/regionally advanced neuroendocrine tumor",
                    "criterion": "neuroendocrine tumor",
                    "requirements": [
                        {
                            "requirement_type": "locally/regionally advanced",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented history of carcinoid syndrome based on clinical parameters",
            "criterions": [
                {
                    "exact_snippets": "Documented history of carcinoid syndrome",
                    "criterion": "carcinoid syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "based on clinical parameters",
                    "criterion": "clinical parameters supporting carcinoid syndrome diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "basis for diagnosis",
                            "expected_value": "clinical parameters"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently receiving stable-dose somatostatin analog (SSA) therapy defined as >= 2 months",
            "criterions": [
                {
                    "exact_snippets": "Currently receiving stable-dose somatostatin analog (SSA) therapy",
                    "criterion": "somatostatin analog (SSA) therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "defined as >= 2 months",
                    "criterion": "duration of stable-dose SSA therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Childbearing potential is defined as those who have not undergone surgical sterilization (eg. documented hysterectomy, tubal ligation, or bilateral salpingo-oophorectomy) or those who are not considered postmenopausal (defined as 12 months of spontaneous amenorrhea).",
            "criterions": [
                {
                    "exact_snippets": "have not undergone surgical sterilization (eg. documented hysterectomy, tubal ligation, or bilateral salpingo-oophorectomy)",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "procedure history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not considered postmenopausal (defined as 12 months of spontaneous amenorrhea)",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "postmenopausal",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "12 months of spontaneous amenorrhea",
                    "criterion": "spontaneous amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate methods of contraception, defined as having a failure rate of < 1% per year, for patients or their partner include the following: condom with spermicidal gel, diaphragm with spermicidal gel, intrauterine device, surgical sterilization, vasectomy, oral contraceptive pill, depo-progesterone injections, progesterone implant (ie, Implanon), patch (Ortho Evra), NuvaRing, and abstinence. If a patient is not sexually active but becomes active, he or his partner should use medically accepted forms of contraception",
            "criterions": [
                {
                    "exact_snippets": "Adequate methods of contraception, defined as having a failure rate of < 1% per year",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "failure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients or their partner include the following: condom with spermicidal gel, diaphragm with spermicidal gel, intrauterine device, surgical sterilization, vasectomy, oral contraceptive pill, depo-progesterone injections, progesterone implant (ie, Implanon), patch (Ortho Evra), NuvaRing, and abstinence",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "method type",
                            "expected_value": [
                                "condom with spermicidal gel",
                                "diaphragm with spermicidal gel",
                                "intrauterine device",
                                "surgical sterilization",
                                "vasectomy",
                                "oral contraceptive pill",
                                "depo-progesterone injections",
                                "progesterone implant (Implanon)",
                                "patch (Ortho Evra)",
                                "NuvaRing",
                                "abstinence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "If a patient is not sexually active but becomes active, he or his partner should use medically accepted forms of contraception",
                    "criterion": "contraception use upon sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "use of contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Unable or unwilling to communicate or cooperate with the Investigator for any reason",
            "criterions": [
                {
                    "exact_snippets": "Unable or unwilling to communicate or cooperate with the Investigator for any reason",
                    "criterion": "ability to communicate or cooperate with the Investigator",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of substance or alcohol abuse (Diagnostic and Statistical Manual of Mental Disorders 5th edition [DSM-V] Criteria for Substance-Related Disorders) within the past 2 years",
            "criterions": [
                {
                    "exact_snippets": "History of substance or alcohol abuse (Diagnostic and Statistical Manual of Mental Disorders 5th edition [DSM-V] Criteria for Substance-Related Disorders) within the past 2 years",
                    "criterion": "substance or alcohol abuse",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "DSM-V Criteria for Substance-Related Disorders"
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arrhythmia causing hemodynamic compromise",
            "criterions": [
                {
                    "exact_snippets": "Arrhythmia causing hemodynamic compromise",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "causing hemodynamic compromise"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant (as per primary investigators judgement) cardiac arrhythmia, bradycardia, tachycardia that would compromise patient safety or the outcome of the study",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant (as per primary investigators judgement) cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator judgement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant (as per primary investigators judgement) ... bradycardia",
                    "criterion": "bradycardia",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator judgement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant (as per primary investigators judgement) ... tachycardia",
                    "criterion": "tachycardia",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator judgement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy < 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy < 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of any clinically significant findings (relative to the patient population) during review of medical history or upon PE that, in the investigator's opinion, would compromise patient safety or the outcome of the study (e.g., psychiatric illness/social situations that would limit compliance with study requirements)",
            "criterions": [
                {
                    "exact_snippets": "Presence of any clinically significant findings ... during review of medical history or upon PE ... that, in the investigator's opinion, would compromise patient safety or the outcome of the study",
                    "criterion": "clinically significant findings",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "impact on safety or study outcome",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatic laboratory values of aspartate transaminase (AST) or alanine aminotransferase (ALT):",
            "criterions": [
                {
                    "exact_snippets": "Hepatic laboratory values of aspartate transaminase (AST)",
                    "criterion": "aspartate transaminase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "laboratory value",
                            "expected_value": "hepatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatic laboratory values of ... alanine aminotransferase (ALT)",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "laboratory value",
                            "expected_value": "hepatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study including as per primary investigators judgement, but not limited to:",
            "criterions": [
                {
                    "exact_snippets": "Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study",
                    "criterion": "cardiac-related abnormality",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "as per primary investigators judgement",
                    "criterion": "primary investigator judgement",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "at the discretion of the primary investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic severe valvular disease",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic severe valvular disease",
                    "criterion": "valvular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable angina pectoris",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina pectoris",
                    "criterion": "unstable angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Existence of any surgical or medical condition that, in the judgment of the Investigator, might compromise patient safety or the outcome of the study",
            "criterions": [
                {
                    "exact_snippets": "Existence of any surgical or medical condition that, in the judgment of the Investigator, might compromise patient safety or the outcome of the study",
                    "criterion": "surgical or medical condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to compromise patient safety or study outcome",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated glomerular filtration rate estimated glomerular filtration rate (eGFR) < 30 ml/min",
            "criterions": [
                {
                    "exact_snippets": "estimated glomerular filtration rate (eGFR) < 30 ml/min",
                    "criterion": "estimated glomerular filtration rate (eGFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic congestive heart failure classified by New York Heart Association (NYHA) class IV",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic congestive heart failure classified by New York Heart Association (NYHA) class IV",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "NYHA classification",
                            "expected_value": "class IV"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients receiving everolimus due to poor response to SSA",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving everolimus",
                    "criterion": "everolimus treatment",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "poor response to SSA",
                    "criterion": "response to SSA",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "poor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Investigator assessment of known history and/or uncontrolled hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV)-1 or HIV-2",
            "criterions": [
                {
                    "exact_snippets": "known history and/or uncontrolled hepatitis B surface antigen (HBsAg)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "known history and/or uncontrolled ... hepatitis C antibody (HCV Ab)",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "known history and/or uncontrolled ... human immunodeficiency virus (HIV)-1 or HIV-2",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating patients",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... patients",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating patients",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of short bowel syndrome or other known causes of diarrhea unrelated to carcinoid syndrome",
            "criterions": [
                {
                    "exact_snippets": "History of short bowel syndrome",
                    "criterion": "short bowel syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other known causes of diarrhea unrelated to carcinoid syndrome",
                    "criterion": "causes of diarrhea unrelated to carcinoid syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any tumor directed therapy, including interferon, chemotherapy, mechanistic target of rapamycin (mTOR) inhibitors < 4 weeks prior to screening, or hepatic embolization, radiotherapy, peptide receptor radionuclide therapy, and/or tumor debulking < 12 weeks prior to screening",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any tumor directed therapy, including interferon, chemotherapy, mechanistic target of rapamycin (mTOR) inhibitors < 4 weeks prior to screening",
                    "criterion": "tumor directed therapy (interferon, chemotherapy, mTOR inhibitors)",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatic embolization, radiotherapy, peptide receptor radionuclide therapy, and/or tumor debulking < 12 weeks prior to screening",
                    "criterion": "hepatic embolization, radiotherapy, peptide receptor radionuclide therapy, tumor debulking",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* > 5 x upper limit of normal (ULN) if patient has documented history of hepatic metastases; or",
            "criterions": [
                {
                    "exact_snippets": "> 5 x upper limit of normal (ULN) if patient has documented history of hepatic metastases",
                    "criterion": "hepatic metastases",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "> 5 x upper limit of normal (ULN) if patient has documented history of hepatic metastases",
                    "criterion": "laboratory value (unspecified)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of any investigational agent or study treatment (other treatment nor approved by Food and Drug Administration [FDA] for carcinoid syndrome or carcinoid heart disease) within the past 30 days",
            "criterions": [
                {
                    "exact_snippets": "Receipt of any investigational agent ... within the past 30 days",
                    "criterion": "receipt of investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Receipt of any ... study treatment (other treatment nor approved by Food and Drug Administration [FDA] for carcinoid syndrome or carcinoid heart disease) within the past 30 days",
                    "criterion": "receipt of non-FDA-approved treatment for carcinoid syndrome or carcinoid heart disease",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* > 2.5 x ULN if no liver metastases are present",
            "criterions": [
                {
                    "exact_snippets": "> 2.5 x ULN if no liver metastases are present",
                    "criterion": "laboratory value (unspecified)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "liver metastases presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of galactose intolerance, deficiency of Lapp lactase, or glucose-galactose malabsorption",
            "criterions": [
                {
                    "exact_snippets": "History of galactose intolerance",
                    "criterion": "galactose intolerance",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "deficiency of Lapp lactase",
                    "criterion": "Lapp lactase deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "glucose-galactose malabsorption",
                    "criterion": "glucose-galactose malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other clinically significant laboratory abnormality that would compromise patient safety or the outcome of the study as per primary investigators judgement",
            "criterions": [
                {
                    "exact_snippets": "Any other clinically significant laboratory abnormality that would compromise patient safety or the outcome of the study as per primary investigators judgement",
                    "criterion": "clinically significant laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on patient safety or study outcome",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "primary investigator judgement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of ischemia on electrocardiography (ECG) with chest pain",
            "criterions": [
                {
                    "exact_snippets": "Evidence of ischemia on electrocardiography (ECG)",
                    "criterion": "ischemia on electrocardiography (ECG)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chest pain",
                    "criterion": "chest pain",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Patients who cannot tolerate SSA therapy at a level indicated above will be allowed to enter at their highest tolerated dose",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Previous exposure to telotristat ethyl (XERMELO) in the last 3 months",
            "criterions": []
        },
        {
            "line": "* History of active treatment for malignancy, other than neuroendocrine tumor (malignancies that in the opinion of the Investigator are considered cured, may participate)",
            "criterions": []
        },
        {
            "line": "* Current complaints of persistent constipation or history of chronic constipation, bowel obstruction or fecaloma within the past 6 months",
            "criterions": [
                {
                    "exact_snippets": "Current complaints of persistent constipation",
                    "criterion": "persistent constipation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of chronic constipation",
                    "criterion": "chronic constipation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bowel obstruction within the past 6 months",
                    "criterion": "bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "fecaloma within the past 6 months",
                    "criterion": "fecaloma",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}